Melodia Therapeutics

What Melodia Therapeutics does

Melodia Therapeutics is a privately held, clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, developing a next-generation dipeptidyl peptidase 1 (DPP1) inhibitor for the treatment of severe neutrophil-driven inflammatory diseases. Its lead program, MLD-151, was in-licensed from Japan/US-based partner Alivexis in 2022 and is built on a proprietary chemotype discovered by Alivexis; a U.S. patent covering this compound series was granted in February 2026. The company's mechanism of action is differentiated from earlier DPP1 inhibitors by avoiding the highly reactive nitrile warhead, instead relying on selective, non-covalent enzyme inhibition intended to deliver improved efficacy and safety in a best-in-class profile.

Melodia's pipeline targets unmet medical needs across respiratory, dermatologic, and systemic inflammatory disorders. The company operates with a lean 11-50 employee footprint and a leadership team anchored by CEO Jonathan Talbot, PhD (ex-Roche Global Scientific Director, ex-Mosanna Therapeutics CEO), Chairman Sven Zimmermann, PhD (CEO of Inotrem SA), and co-founders Sascha Oliver Bucher and Sara Núñez-García of Forty51 Ventures. Scientific and clinical advisory support is provided by senior KOLs with credentials from Roche, Boehringer Ingelheim, Merck, GlaxoWellcome, Verona Pharma, and academic respiratory pharmacology (King's College London, University of Manchester, University of Michigan).

Melodia is pre-revenue with no approved or commercialized products, generating no disclosed sales or licensing income. Its go-to-market model is the conventional biopharma clinical development pathway: advance MLD-151 through clinical trials toward regulatory approval and eventual commercialization, supported by global scientific advisors and conference engagement rather than direct sales. Publicly visible pricing on the company's website is generic template content (medical Webflow template; subscription tiers of $39/$69/$99) and does not reflect the company's actual business model. Customer base consists of future patients and potential pharma partners in respiratory and inflammatory indications rather than direct enterprise buyers.

Name

Melodia Therapeutics

Legal name

Melodia Therapeutics

Website

https://melodiatx.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Melodia Therapeutics is a Basel-based, clinical-stage biotech developing MLD-151, a next-generation non-covalent DPP1 inhibitor licensed from Alivexis, to treat severe neutrophil-driven respiratory, dermatologic, and systemic inflammatory diseases.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

akta.pro secondary industry

COPD & Chronic Bronchitis Management (HLAKANAE)

Keywords

• DPP1 inhibitor development
• Neutrophil-driven inflammatory disease
• Anti-granulocyte therapy
• Clinical-stage biopharmaceuticals
• Respiratory inflammation therapeutics

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels2 records

Core offering

Melodia Therapeutics is a clinical-stage biopharmaceutical company developing MLD-151, a next-generation DPP1 (dipeptidyl peptidase 1) inhibitor for the treatment of severe neutrophil-driven inflammatory diseases. The asset was licensed from partner Alivexis and is being advanced through preclinical and clinical development with the goal of becoming a best-in-class therapy in respiratory, dermatologic, and systemic inflammatory indications.

Product overview

Melodia Therapeutics is a biotech company advancing a single clinical-stage asset, MLD-151, a next-generation DPP1 inhibitor for treating severe neutrophil-driven inflammatory diseases. The company's approach focuses on selective DPP1 inhibition without covalent attachment, targeting improved efficacy and safety compared to earlier agents. Melodia is building a pipeline addressing unmet needs in respiratory, dermatologic, and systemic inflammatory disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• MLD-151

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Aristea Therapeutics: Aristea is a clinical-stage biotech developing therapies for neutrophil-driven inflammatory diseases, including DPP1-pathway programs. Aristea directly competes with Melodia in mechanism (DPP1/cathepsin C), patient population (severe neutrophilic inflammation), and development stage.
• Insmed Incorporated: Insmed is developing brensocatib, a leading DPP1 (cathepsin C) inhibitor in advanced clinical trials for bronchiectasis and other neutrophil-driven inflammatory diseases. Melodia's MLD-151 targets the same enzyme pathway, making Insmed the most directly comparable peer on mechanism, indication overlap, and competitive dynamic.

Broad incumbents

• Arcutis Biotherapeutics: Arcutis develops and commercializes therapies for inflammatory skin diseases (e.g., atopic dermatitis, psoriasis), directly overlapping with Melodia's dermatologic inflammatory segment. As a peer, Arcutis represents the commercial model and competitive context for Melodia's potential label expansion into dermatologic inflammatory disorders.
• AnaptysBio: AnaptysBio is a clinical-stage immunology company developing antibody therapeutics for inflammatory diseases. While AnaptysBio targets upstream immunological pathways rather than DPP1 directly, both companies share the neutrophil/inflammatory disease focus and a clinical-stage development profile.
• AstraZeneca: AstraZeneca is a major respiratory and immunology franchise holder (Symbicort, Fasenra, Trixeo, etc.) and previously held rights to DPP1 chemistry (brensocatib was originally an AZ asset). AZ is comparable as both a respiratory competitor and a potential strategic partner or acquirer for late-stage Melodia assets.
• Verona Pharma: Verona Pharma developed ensifentrine, a novel therapy for chronic respiratory diseases, and was acquired by Merck. Verona is a relevant comparable because it targeted neutrophil/inflammatory respiratory biology and was acquired at scale by a major pharma, framing Melodia's respiratory-inflammation development path and potential exit profile.
• Boehringer Ingelheim: Boehringer Ingelheim is a major respiratory and inflammatory disease company that has previously worked on DPP1-related neutrophil biology and currently markets several respiratory therapies. Melodia's clinical advisory team includes former BI pulmonology leadership, and BI represents both a competitive incumbent and a potential strategic acquirer.
• ChemoCentryx (a Sanofi company): ChemoCentryx, acquired by Sanofi for $4.9B, pioneered complement/chemokine-based anti-inflammatory therapeutics. It is comparable to Melodia as a small-cap anti-inflammatory drug developer that scaled via strategic acquisition, providing a relevant exit-strategy reference for clinical-stage inflammation biotechs.

Emerging players

• Kymera Therapeutics: Kymera is a clinical-stage biotech developing targeted protein degradation therapies for immunology and inflammatory diseases. While Kymera's modality is distinct, it shares Melodia's clinical-stage status and focus on inflammation biology, making it a comparable peer for translational and capital-markets dynamics.
• UNION Therapeutics: UNION is a privately held clinical-stage biotech focused on inflammatory and immunology indications with both dermatology and respiratory assets. UNION's diversified inflammatory pipeline and clinically-driven model offers a comparison point for Melodia's label-expansion strategy beyond a single asset.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/melodia-therapeutics-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Melodia Therapeutics